KR100607742B1 - 안정한 액상 현탁제, 및 이를 함유하는, 생체 이용율이 증진된 항진균성 조성물 - Google Patents

안정한 액상 현탁제, 및 이를 함유하는, 생체 이용율이 증진된 항진균성 조성물 Download PDF

Info

Publication number
KR100607742B1
KR100607742B1 KR1020037012936A KR20037012936A KR100607742B1 KR 100607742 B1 KR100607742 B1 KR 100607742B1 KR 1020037012936 A KR1020037012936 A KR 1020037012936A KR 20037012936 A KR20037012936 A KR 20037012936A KR 100607742 B1 KR100607742 B1 KR 100607742B1
Authority
KR
South Korea
Prior art keywords
suspending agent
liquid
posaconazole
sorbitan
liquid suspending
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020037012936A
Other languages
English (en)
Korean (ko)
Other versions
KR20030087052A (ko
Inventor
샤르페스테판
세퀘이라조엘
해리스데이비드
마하샤브드샤샨크
Original Assignee
쉐링 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23076102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100607742(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 쉐링 코포레이션 filed Critical 쉐링 코포레이션
Publication of KR20030087052A publication Critical patent/KR20030087052A/ko
Application granted granted Critical
Publication of KR100607742B1 publication Critical patent/KR100607742B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/64—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with three nitrogen atoms as the only ring hetero atoms
    • A01N43/647—Triazoles; Hydrogenated triazoles
    • A01N43/653—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dentistry (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Agronomy & Crop Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020037012936A 2001-04-03 2002-04-01 안정한 액상 현탁제, 및 이를 함유하는, 생체 이용율이 증진된 항진균성 조성물 Expired - Lifetime KR100607742B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28113901P 2001-04-03 2001-04-03
US60/281,139 2001-04-03
PCT/US2002/010093 WO2002080678A1 (en) 2001-04-03 2002-04-01 Antifungal composition with enhanced bioavailability

Publications (2)

Publication Number Publication Date
KR20030087052A KR20030087052A (ko) 2003-11-12
KR100607742B1 true KR100607742B1 (ko) 2006-08-01

Family

ID=23076102

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037012936A Expired - Lifetime KR100607742B1 (ko) 2001-04-03 2002-04-01 안정한 액상 현탁제, 및 이를 함유하는, 생체 이용율이 증진된 항진균성 조성물

Country Status (18)

Country Link
US (2) US20030055067A1 (enExample)
EP (2) EP1372394A1 (enExample)
JP (2) JP4308902B2 (enExample)
KR (1) KR100607742B1 (enExample)
CN (1) CN100415234C (enExample)
AR (1) AR033096A1 (enExample)
AU (1) AU2002257104B2 (enExample)
BR (1) BR0208626A (enExample)
CA (1) CA2443089C (enExample)
HU (1) HUP0400856A3 (enExample)
MX (1) MXPA03009021A (enExample)
NO (1) NO20034419L (enExample)
NZ (1) NZ528363A (enExample)
PE (1) PE20020994A1 (enExample)
PL (1) PL212985B1 (enExample)
TW (1) TWI311464B (enExample)
WO (1) WO2002080678A1 (enExample)
ZA (1) ZA200307684B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
WO2003026611A2 (en) 2001-09-26 2003-04-03 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
AU2005249502A1 (en) * 2004-05-28 2005-12-15 Schering Corporation Particulate-stabilized injectable pharmaceutical compositions of posaconazole
US20060009469A1 (en) * 2004-05-28 2006-01-12 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmacutical compositions of posaconazole
US20060160823A1 (en) * 2004-05-28 2006-07-20 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmaceutical compositions of Posaconazole
US7473684B2 (en) * 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
CN101495096A (zh) 2006-05-30 2009-07-29 伊兰制药国际有限公司 纳米微粒泊沙康唑制剂
MX2008015764A (es) 2006-06-14 2009-01-07 Intervet Int Bv Suspension que comprende carbamato de bencimidazol y polisorbato.
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
FR2910323A1 (fr) * 2006-12-26 2008-06-27 Virbac Sa Sa Composition liquide anhydre destinee a etre incorporee a l'eau de boisson des animaux d'elevage.
DE102008004893A1 (de) 2008-01-17 2009-07-23 Add Technologies Ltd. Trägerpellets, Verfahren zu deren Herstellung und deren Verwendung
JP2011516613A (ja) * 2008-04-15 2011-05-26 シェーリング コーポレイション 好ましくはポサコナゾールおよびｈｐｍｃａｓを含む固体分散物中の経口用薬学的組成物
SG10201403986UA (en) * 2008-04-15 2014-10-30 Merck Sharp & Dohme High Density Compositions Containing Posaconazole And Formulations Comprising The Same
EP2130540A1 (en) 2008-06-02 2009-12-09 Sandoz AG Pharmaceutical compositions containing a crystalline form of posaconazole
EP2141159A1 (en) 2008-07-03 2010-01-06 Sandoz AG A Crystalline form of posaconazole
WO2011003992A1 (en) 2009-07-09 2011-01-13 Sandoz Ag A crystalline form of posaconazole
CN102892762B (zh) 2010-05-19 2016-04-20 桑多斯股份公司 制备泊沙康唑中间体
BR112012029227B1 (pt) 2010-05-19 2020-01-07 Sandoz Ag Processo para a preparação de um composto quiral, composto quiral e uso de um composto
BR112012029225B1 (pt) 2010-05-19 2020-10-27 Sandoz Ag processo para a preparação de um composto quiral, composto quiral e uso de um composto quiral
MX2012013331A (es) 2010-05-19 2013-02-01 Sandoz Ag Purificacion de posaconazol y de intermediarios de posaconazol.
CA2838051C (en) 2011-06-16 2019-09-24 Sandoz Ag Process for the preparation of a chiral compound
CA2874797A1 (en) 2012-06-14 2013-12-19 Sandoz Ag Pharmaceutical composition comprising crystalline posaconazole
JP6669751B2 (ja) 2014-12-05 2020-03-18 プルモシデ リミテド 抗真菌化合物
WO2016185225A1 (en) 2015-05-21 2016-11-24 Pulmocide Limited Antifungal 4-(4-(4-(((3r,5r)-5-((1 h -1,2,4-triazol-1 -yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)- 3-methylphenyl)piperazin-1 -yl )-n -(2-h yd roxycyc lo h exyl) b e nzam i d e, or a pharmaceutically acceptable salt thereof.
CN105030668B (zh) * 2015-06-26 2018-03-27 济川药业集团有限公司 泊沙康唑口服混悬剂及其制备方法
CN106333925B (zh) * 2015-07-10 2019-06-18 上海美悦生物科技发展有限公司 一种泊沙康唑液体混悬剂及其制备方法
JP6803923B2 (ja) 2015-12-30 2020-12-23 エヌキューピー １５９８，リミテッド 金属酵素阻害化合物
CN106389390A (zh) * 2016-06-30 2017-02-15 重庆华邦制药有限公司 泊沙康唑涂膜剂及其制备方法
CN107625729A (zh) * 2017-09-29 2018-01-26 重庆华邦制药有限公司 泊沙康唑口服混悬液及其制备方法
CN110507609B (zh) * 2018-05-21 2021-09-17 上海医药工业研究院 泊沙康唑口服混悬剂的制备方法
GB201917867D0 (en) 2019-12-06 2020-01-22 Pulmocide Ltd Polymorphs
US20230219936A1 (en) * 2020-05-12 2023-07-13 Cellix Bio Private Limited Process for the preparation salts of triazole compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4533254A (en) 1981-04-17 1985-08-06 Biotechnology Development Corporation Apparatus for forming emulsions
US4788220A (en) * 1987-07-08 1988-11-29 American Home Products Corporation (Del.) Pediatric ibuprofen compositions
NZ234143A (en) * 1989-06-28 1991-10-25 Mcneil Ppc Inc Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
AU642066B2 (en) 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5661151A (en) * 1993-12-21 1997-08-26 Schering Corporation Tetrahydrofuran antifungals
HU225062B1 (en) * 1993-12-21 2006-05-29 Schering Corp Tetrahydrofuran derivatives with antifungal- effect, pharmaceutical compositions containing them and process for their preparation
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5580579A (en) * 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
WO1997018821A1 (en) * 1995-11-20 1997-05-29 Banyu Pharmaceutical Co., Ltd. Antifungal composition
US5834472A (en) * 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
US5846971A (en) 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
EP0995435B1 (en) * 1997-05-14 2007-04-25 Senju Pharmaceutical Co., Ltd. Aqueous suspension preparations with excellent redispersibility
JP2002516267A (ja) 1998-05-29 2002-06-04 アールティーピー・ファーマ・インコーポレーテッド 熱的に保護された微粒子組成物及びその最終蒸気滅菌
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug

Also Published As

Publication number Publication date
NO20034419L (no) 2003-12-02
EP1372394A1 (en) 2004-01-02
PL363965A1 (en) 2004-11-29
PE20020994A1 (es) 2002-11-01
US8263600B2 (en) 2012-09-11
BR0208626A (pt) 2004-03-09
JP2004527525A (ja) 2004-09-09
HUP0400856A2 (hu) 2004-08-30
HUP0400856A3 (en) 2012-09-28
MXPA03009021A (es) 2004-02-12
NO20034419D0 (no) 2003-10-02
CN1499930A (zh) 2004-05-26
TWI311464B (en) 2009-07-01
ZA200307684B (en) 2005-03-30
KR20030087052A (ko) 2003-11-12
EP2090165A3 (en) 2012-03-28
AR033096A1 (es) 2003-12-03
WO2002080678A1 (en) 2002-10-17
EP2090165A2 (en) 2009-08-19
JP2008120836A (ja) 2008-05-29
CN100415234C (zh) 2008-09-03
CA2443089A1 (en) 2002-10-17
AU2002257104B2 (en) 2006-02-09
PL212985B1 (pl) 2012-12-31
JP4308902B2 (ja) 2009-08-05
US20110244004A1 (en) 2011-10-06
US20030055067A1 (en) 2003-03-20
NZ528363A (en) 2005-04-29
CA2443089C (en) 2011-11-01

Similar Documents

Publication Publication Date Title
KR100607742B1 (ko) 안정한 액상 현탁제, 및 이를 함유하는, 생체 이용율이 증진된 항진균성 조성물
AU2002257104A1 (en) Antifungal composition with enhanced bioavailability
JP5159012B2 (ja) 不良溶解性の薬物に対する改良された医薬組成物
RU2260428C2 (ru) Фармацевтическая композиция, содержащая производное бензамида и обладающая повышенной растворимостью и поглощаемостью при оральном применении
DE4322826A1 (de) Pharmazeutisches Präparat
KR20150058243A (ko) 아픽사반 액체 제제
US20020028794A1 (en) Megestrol acetate suspension
JPH082795B2 (ja) サイクロスポリン含有経口用医薬組成物およびその製造方法
EP3871662B1 (en) Oral solutions comprising fludrocortisone acetate
EP0914127B1 (en) Antifungal composition with enhanced bioavailability
WO2020212898A1 (en) Pharmaceutical oral liquid solution of ivacaftor
WO2024141623A1 (en) Liquid pharmaceutical formulations of quinolines
CN114681432B (zh) 一种丁苯酞组合物及其用途
WO2023218482A1 (en) Liquid oral formulation of apixaban or pharmaceutically acceptable salt thereof
AU762963B2 (en) Cyclosporin solution
HK1129053A (en) Antifungal composition with enhanced bioavailability
AU2006200354A1 (en) Antifungal composition with enhanced bioavailability
KR100341203B1 (ko) 유성 비타민 함유 약학 조성물 및 이의 제조방법
KR20110042874A (ko) 메게스트롤 아세테이트를 포함하는 현탁제
KR100581169B1 (ko) 용해도가 개선된 테르비나핀의 약제조성물 및 그 제조방법
US20060141028A1 (en) Cyclosporin formulations
US20240058306A1 (en) Novel oral liquid compositions of enzalutamide and method of manufacturing thereof
CN119677520A (zh) 醋酸阿比特龙口服制剂及其制备方法
SK126998A3 (en) Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20031002

Patent event code: PA01051R01D

Comment text: International Patent Application

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20031030

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20050530

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20060501

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20060725

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20060725

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20090630

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20100630

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20110629

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20120628

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20130628

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20130628

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20140627

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20140627

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20150630

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20160629

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20160629

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20180628

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20180628

Start annual number: 13

End annual number: 13

FPAY Annual fee payment

Payment date: 20190624

Year of fee payment: 14

PR1001 Payment of annual fee

Payment date: 20190624

Start annual number: 14

End annual number: 14

PR1001 Payment of annual fee

Payment date: 20200624

Start annual number: 15

End annual number: 15

PC1801 Expiration of term

Termination date: 20221001

Termination category: Expiration of duration